Not all compounds are suitable starting points for drug development due to undesirable pharmacokinetic properties, which for instance negatively affect a drug's absorption, distribution, metabolism, and excretion (ADME). Therefore, such compounds are usually not included in data sets for virtual screening. In order to remove less drug-like molecules from the EGFR data set, the following steps are conducted:
1.Calculate 1D chemical properties (MW, HBD, HBA, LogP)
2.Filter dataset by Lipinski's rule of five
3.Visualize dataset properties with box plot
Author:
Dominique Sydow, Michele Wichmann, Jaime Rodríguez-Guerra, Daria Goldmann, Gregory Landrum, and Andrea Volkamer
Workflow
Used extensions & nodes
Created with KNIME Analytics Platform version 4.5.1
Note: Not all extensions may be displayed.
- Go to item
- Go to item
- Go to item
- Go to item
- Go to item
- Go to item
Loading deployments
Loading ad hoc executions
Legal
By using or downloading the workflow, you agree to our terms and conditions.
Discussion
Discussions are currently not available, please try again later.